Griffin Myers - May 2, 2023 Form 4 Insider Report for Oak Street Health, Inc. (OSH)

Signature
/s/ Robert Guenthner, attorney-in-fact for Griffin Myers
Stock symbol
OSH
Transactions as of
May 2, 2023
Transactions value $
-$220,689,239
Form type
4
Date filed
5/2/2023, 07:53 PM
Previous filing
Mar 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OSH Common stock, $0.001 par value Gift $0 -8.5K -0.18% $0.00 4.85M Dec 8, 2021 Through Griffin R. Myers Revocable Trust u/a/d 5/26/2020
transaction OSH Common stock, $0.001 par value Disposed to Issuer -$332K -8.51K -100% $39.00 0 May 2, 2023 Direct F1, F3, F4
transaction OSH Common stock, $0.001 par value Disposed to Issuer -$189M -4.85M -100% $39.00 0 May 2, 2023 Through Griffin R. Myers Revocable Trust u/a/d 5/26/2020 F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OSH Employee Stock Option (Right to Buy) Disposed to Issuer -$30.2M -1.68M -100% $18.00 0 May 2, 2023 Common stock, $0.001 par value 1.68M $21.00 Through Griffin R. Myers Revocable Trust u/a/d 5/26/2020 F5, F6
transaction OSH Performance Stock Option (Right to Buy) Disposed to Issuer -$1.18M -50.9K -100% $23.25 0 May 2, 2023 Common stock, $0.001 par value 50.9K $15.75 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Griffin Myers is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the Issuer, CVS Pharmacy, Inc. ("Parent"), Halo Merger Sub Corp. ("Merger Sub") and, for the limited purposes set forth therein, CVS Health Corporation ("CVS Health"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $39.00 per share in cash, without interest and subject to applicable tax withholdings (the "Per Share Price").
F2 The shares of the Issuer's common stock reported as disposed by the Reporting Person include restricted stock awards which were, at the Effective Time, automatically assumed by Parent and converted into a corresponding CVS Health restricted stock award, as provided under the Merger Agreement.
F3 The shares of the Issuer's common stock reported as disposed by the Reporting Person include: (a) vested restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time, (b) unvested RSUs of the Issuer granted on or after February 7, 2023 which were, at the Effective Time, automatically assumed by Parent and converted into a corresponding CVS Health RSU award, subject to the terms and conditions (including applicable vesting provisions) as provided under the Merger Agreement, and
F4 (Continued from Footnote 3) (c) unvested RSUs of the Issuer granted before February 7, 2023 which were, at the Effective Time, automatically cancelled and converted into the contractual right to receive a an amount in cash (without interest and subject to applicable withholdings) equal to the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time, subject to the same terms and conditions (including applicable vesting provisions) as applied to such RSUs immediately prior to the Effective Time, except as provided under the Merger Agreement.
F5 Pursuant to the Merger Agreement, at the Effective Time, (a) the vested portion of this option was automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock subject to such option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such vested portion of the option and
F6 (Continued from Footnote 5) (b) the unvested portion of this option was automatically cancelled and converted into the contractual right to receive a payment in cash (without interest and subject to applicable tax withholding) equal to the number of shares of the Issuer's common stock subject to such unvested portion of the option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such option, subject to the same terms and conditions (including applicable vesting provisions) as applied to such option immediately prior to the Effective Time, except as provided under the Merger Agreement.
F7 The performance-based stock options ("PSOs") previously issued to the Reporting Person automatically vested at the maximum level of performance achievement in connection with the Merger (which constituted a Change of Control, as defined in the PSO award agreement). Pursuant to the Merger Agreement, the PSOs were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock underlying such PSOs as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such PSOs.